<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>CORTICOSTEROIDS</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\25.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>CORTICOSTEROIDS <a name='24:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
<img src="./Pharmacology/pasted_image.png">
</p>
<h1>OVERVIEW</h1>

<p>
→ adrenal gland consist of <br>
<ul style='padding-left: 30pt'>
<li>cortex [adrenocorticoisteroids (glucocricoids,minerlacorticoids) + adrenal androgen</li>
<li>medulla [epinephrine]</li>
</ul>
→ adrenal cortex  divided into three zone [synthesize steroids from cholesterol]<br>
1.Outer zone glomerulosa produce<br>
<ul style='padding-left: 30pt'>
<li>mineralcorticoids (aldosterone)
<ul>
<li>which is responsible for regulating salt and water</li>
</ul></li>
</ul>
2.Middle zone fasciculata<br>
<ul style='padding-left: 30pt'>
<li>glucocorticoids (cortisol)
<ul>
<li>invovled with normal meatbolism and resistance to stress.</li>
</ul></li>
</ul>
3.Inner zona reticularis <br>
<ul style='padding-left: 30pt'>
<li>secretes adrenal androgens (dehydroepiandrosterone)</li>
</ul>
→ secretion by two inner zones and some extend from the outer is controlled by <br>
<ul style='padding-left: 30pt'>
<li>ACTH [pituitary adrenocorticitropic hormone] - [ corticotropin ]
<ul>
<li>which released in response to CRH [hypothalamic corticitrioin-releasing hormone] - [croticotropin-releasing factor]</li>
</ul></li>
</ul>
→ Glucocorticoids serve as 	<br>
<ul style='padding-left: 30pt'>
<li>feedback inhibitors of corticotropin and CRH secretion.</li>
</ul>
→ hormones of the adrenal cortex used in replacement therapy<br>
<ul style='padding-left: 30pt'>
<li>treatment and managment of asthma</li>
<li>other inflammatory diseases</li>
<li>treatment of severe allergic reactions</li>
<li>treatment of some cancers.</li>
</ul>
</p>

<h1>ADRENOCROTICOSTEROIDS</h1>

<p>
→ bind to specific intracellular cytoplasmic receptors in target tissues
</p>

<p>
[<i>glucocorticoid receptors are widely distributed throughout the body,while mineralcorticoids confined mainly in the excretory organs such as kidney,colon and salivary/sweat glands] — [ both found in the brain]</i>
</p>

<p>
→ after dimerizing <br>
<ul style='padding-left: 30pt'>
<li>receptor-hormone recruit co-activator proteins
<ul>
<li>complex translocates into the nucleus
<ul>
<li>where attaches to gene promoter elements.
<ul>
<li>acting as transcription factor to turn genes on.</li>
</ul></li>
</ul></li>
</ul>
</li>
<li>this mechanism requires time to produce an effect.</li>
</ul>
→ other glucocorticoid effects such as their catecholamines to mediate relaxation of bronchial musculature or lipolysis.
</p>

<h1>GLUCOCORTICOIDS</h1>

<p>
<img src="./Pharmacology/pasted_image002.png"><br>
→ <i>Cortisol </i> is the principle human glucocorticoid.<br>
→ production is diurnal<br>
<ul style='padding-left: 30pt'>
<li>with peak early in the morning 
<ul>
<li>followed by decline and then
<ul>
<li>secondary,smaller peak in the late afternoon.</li>
</ul></li>
</ul></li>
</ul>
→ factos such as stress and levels of the circulating setroid influence secretion.<br>
1.Promote normal intermediary metabolism
</p>

<p>
→ gluco. favor gluconeogenesis through ↑ amino acid uptake by the liver and kidney <br>
→ stimulate protein catabolism and lipolysis.<br>
<ul style='padding-left: 30pt'>
<li>providing building blocks and energy that are needed for glucose synthesis.</li>
</ul>
[<i>gluco. insufficiency may result in hypoglycemia]</i><br>
→ lipolysis results as a consequency of the glucorticoid augmenting the action of growth hormone on adipocytes.<br>
<ul style='padding-left: 30pt'>
<li>causing an ↑ in the activity of hormone-sensitive lipase.</li>
</ul>
</p>

<p>
2.Increase resistance to stress<br>
→ ↑ plasma glucose levels<br>
<ul style='padding-left: 30pt'>
<li>gluco. provides the body with energy it requires to combact stress.</li>
</ul>
→ can cause modest rise on blood pressure,<br>
<ul style='padding-left: 30pt'>
<li>by enhancing the vasoconstrictor action of adrenergic stimuli on small vessels.</li>
</ul>
3.Alter blood cell levels in plasma.<br>
→ ↓  in eosinophilis,basophilis,monocytes and lymphocytes<br>
<ul style='padding-left: 30pt'>
<li>by resdistributing them from the circulation to lymphoid tissue.
<ul>
<li>in contrast to this effect,gluco. increase the blood levels of hemoglobin,erythrocytes,platels,</li>
</ul></li>
</ul>
<i>[↓ in cicrculating lymphocytes and macrophages compromises the body's ability to fight infecntion,though it is important in the treatment of leukemia ]</i><br>
4.Have anti-inflammatory action<br>
→ important therepeutic property of the gluco. is their ability to ↓ the inflammataory process and supress immunity.<br>
→ moa is complex and incompletely understood<br>
→ also involved in the indirect inhibition of phospholipase A2 [due to the steroid-mediated elevation of lipocortin]<br>
<ul style='padding-left: 30pt'>
<li>which blocks the release of arachidonic acid</li>
</ul>
→ cycloxegenase-2 synthesis is further ↓<br>
→ mast cell degranulation results in ↓ histamaine and capillary permability.<br>
5.Affect other compenents of the endocrine system<br>
→ feedback inhibition of corticotropin production by elevated glucocorticoids cauases inhibition of further synthesis of both<br>
glucocorticoid and thyroid-stimulating hormones.
</p>

<p>
6.Can have effects on other systems<br>
→ cortistol levels are essential for normal glomerular filtration.<br>
→ effects of corticosteroids on other systems are mostsly associated with the advrese effects of the hormones.<br>
→ high doses of gluco. stimulate<br>
<ul style='padding-left: 30pt'>
<li>gastric acid and pepsin production and may exacerbate ulcers.</li>
</ul>
→ mental status affected<br>
→ chronic gluco. therapy can → severe bone loss and myopathy
</p>

<h1>MINERALCORTICOIDS</h1>

<p>
→ help to control the body's<br>
<ul style='padding-left: 30pt'>
<li>water volume</li>
<li>concentration of electrolytes (sodium and potassium)</li>
</ul>
→ Adlosterone acts on kideny tubules and collecting ducts and cause<br>
<ul style='padding-left: 30pt'>
<li>reabsorption of sodium , bicarbonate , water</li>
<li>↓ reabsrorption of potassium and H+ then lost in the urine.</li>
</ul>
→ Enhancment of sodium reabsorption by aldosterone also occur in<br>
<ul style='padding-left: 30pt'>
<li>GIT , sweat and salivary gland</li>
</ul>
→ target cells of aldosterone action contain minerlacorticoid receptors that interact with the hormones in a manner analogous to that of the glucocorticoid receptor.
</p>

<h1>Therapeutic uses of the adrenal corticosteroids</h1>

<p>
1.REPLACEMENT THERAPY FOR PRIMARY ADRENOCORTICAL INSUFFICIENCY (Addison disease)<br>
→ adrenal cortex dysfunction (lack to corticotropin response to corticotropin)<br>
→ <i>Hydrocortistone</i><br>
<ul style='padding-left: 30pt'>
<li>identical to natural cortistol is given to correct the deficiency</li>
<li>dose is divided 
<ul>
<li>2/3 of the normal dose is given in the morning</li>
<li>1/3 in the afternoon</li>
</ul></li>
</ul>
→ <i>Fludrocortistone</i><br>
<ul style='padding-left: 30pt'>
<li>potent synthetic mineralcorticoidsone help to ↑ </li>
</ul>
2.REPLACEMENT THERAPY FOR SECONDARY OR TETRIARY ADRENOCORTICAL INSUFFICIENCY.<br>
→ caused by defect either in CRH production by the hypothalamus or in corticotropin production by the pituitary.<br>
[<i>under these condintion,the synthesis of mineralcorticoids in the adrenal cortex is less impaired than that of glucocorticoids]</i><br>
→ <i>Hydrocortistone </i>is used for treatment of these deficiencies.<br>
3.DIAGNOSIS OF CUSHING SYNDROME<br>
→ is caused by hypersecretion of glucocorticoids that results either from excessive release of corticotropin<br>
by the anterior pituitary or an adrenal tumor.<br>
4.REPLACEMENT THERAPY FOR CONGENITAL ADRENAL HYPERPLASIA<br>
→enzyme defect in the synthesis of one or more of the adrenal steroid hormones.<br>
→ admin. of sufficient corticosteroids to normalize the patient's hormone levels by suprresing<br>
<ul style='padding-left: 30pt'>
<li>release of CRH and ACTH.
<ul>
<li>↓ production of adrenal androgens</li>
</ul></li>
</ul>
→ choice of hormone depends on the specific enezyme defect.<br>
5.RELIEFE OF INFLAMMATAORY SYMPTOMS.<br>
→ because of redistribution of leukocytes to other body compartments<br>
<ul style='padding-left: 30pt'>
<li>↓ blood conc.</li>
</ul>
→ ↑ in conc. of neutrophilis<br>
<ul style='padding-left: 30pt'>
<li>↓ in conc. of lymphocytes(T &amp; B cells).basphilis,eosinophilis,monocytes</li>
<li>and inhibition of th ability of leukocytes and macrophages to respond to mitogens and antigens</li>
</ul>
→ ↓ production of prostagladins and leukotrienes is believed to be central to the anti-inflammatory action<br>
→ also stabilize mast cells and basophil memebranes (inhibiting histamine release)<br>
<ul style='padding-left: 30pt'>
<li>diminishing the activation of the kinin system.</li>
</ul>
6.TREATMENT OF ALLERGIES<br>
→ bronchial asthma,allergic rhinitis and tranfusion allergic reactions.<br>
<ul style='padding-left: 30pt'>
<li>these drugs are not curative</li>
</ul>
→ <i>Triamcinolone and other</i><br>
<ul style='padding-left: 30pt'>
<li>applied topically to the respiratory tract trhough inhalation from a metered dose dispenser.
<ul>
<li>minimizes systemic effects
<ul>
<li>reduce or eliminate the use of oral steroid.</li>
</ul></li>
</ul></li>
</ul>
→ 7.ACCELERATION OF LUNG MUTATION<br>
→ respiratory distress syndrome is a problem in premature infants<br>
→ <i>Betamethasone or dexamethasone </i>intramusculary 	<br>
<ul style='padding-left: 30pt'>
<li>to the mother 48 hours prior to birth</li>
</ul>
<img src="./Pharmacology/pasted_image003.png">
</p>

<h1>PHARMACOKINETICS</h1>

<p>
→ orally and readily absorbed frmo the GIT<br>
→ intravenously , intramuscularrly, intra-articulary , topically, aerosol (oral inhalation,intranasal)<br>
→ 90% is bound to plasma protein<br>
<ul style='padding-left: 30pt'>
<li>globulin and albumin</li>
</ul>
→ metabolized in the liver<br>
<ul style='padding-left: 30pt'>
<li>metabolites conjugated glucuronic acid and sulfate.</li>
</ul>
→ excreted by the kideny<br>
→ half-life may ↑ with hepatic dysfunction.<br>
→ topical therapy may cause<br>
<ul style='padding-left: 30pt'>
<li>skin atrophy ecchymoses , dermatoses and cataracts</li>
</ul>
</p>

<h1>Adverese Effects</h1>

<p>
→ osteoporosis must common adverse effects<br>
<ul style='padding-left: 30pt'>
<li>due to the ability to supress intestinal Ca2+ absorption , inhibit bone formation , ↓ sex synthesis.
<ul>
<li>calcium and vitamin D supplements.</li>
</ul></li>
</ul>
→ Cushing-like syndrome<br>
<ul style='padding-left: 30pt'>
<li>redistribution of body fat, puffy face , ↑body hair growth, isomnia ,↑ appetite.</li>
</ul>
→ cataracts<br>
→ Hyperglycemia may develop and led to diabetes<br>
→ Hypokalemia also occur<br>
<ul style='padding-left: 30pt'>
<li>can be counter acted by potassium supplementantion.</li>
</ul>
</p>

<h1>Withdrawal</h1>

<p>
→ if the patients has ben experianced HPA suppresion	<br>
<ul style='padding-left: 30pt'>
<li>can cause acute adrenal insufficiency syndrome that can be lethal</li>
</ul>
→ dose must be tapered according to the individual<br>
<ul style='padding-left: 30pt'>
<li>possibly through trial and error.</li>
</ul>
</p>

<h1>INHIBITION OF ADRENOCORTICOID BIOSYNTHESIS OR FUNCTION</h1>

<br>

<h1>1.Ketoconazole</h1>

<p>
→ antifugnal agent that strongly inhibit all gonadal and adrenal steroid hormone synthesis.<br>
<ul style='padding-left: 30pt'>
<li>in patients with Cushing syndrome</li>
</ul>
</p>

<h1>2.Spirolactone</h1>

<p>
→ antihypertensive drug competes for the mineralcorticoids receptor <br>
<ul style='padding-left: 30pt'>
<li>inhibit sodium reabsorption in the kideny</li>
</ul>
→ anatagonize aldosterone and testosterone synthesis
</p>

<h1>3.Eplerenone</h1>

<p>
→ specifically bind to the mineralcorticoid receptor<br>
<ul style='padding-left: 30pt'>
<li>acts as aldosterone antagonist
<ul>
<li>this specificity avoids side effects such as gynecomastia that associated with spirolactone.</li>
</ul></li>
</ul>
→ it is approved as an anti-hypertensive.
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>67.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>65.0kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>65.0kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>88.7kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
